โ Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights ๐ข Company Q&A (464) ๐ ๏ธ Industry Q&A (98) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
Date | Press release |
---|---|
2025-05-22 17:00:00 | Daiichi Sankyo Continues To Transform Treatment Landscape For Patients With Cancer With Practice-changing Data At Asco Basking ridge, n.j.--(business wire)--daiichi sankyo (tse: 4568) will present new clinical research across its oncology portfolio with more than 20 abstracts in multiple cancers at the 2025 american society of clinical oncology scientific program (#asco25). data at asco showcasing the companyโs progress towards creating new standards of care for patients with cancer will include two late-breaking oral presentations. the first will feature results of the destiny-breast09 phase 3 trial (lba #1008. |
2025-01-30 23:05:00 | Daiichi Sankyo Appoints Hiroyuki Okuzawa As Chief Executive Officer Tokyo--(business wire)--daiichi sankyo company, ltd (tse: 4568) has appointed hiroyuki okuzawa, 62, to succeed sunao manabe, dvm, ph.d. as chief executive officer (ceo), effective april 1, 2025. dr. manabe will transition from his current role of representative director, executive chairperson and ceo to representative director and executive chairperson while mr. okuzawa will transition to representative director, president and ceo. under dr. manabeโs leadership, daiichi sankyoโs pioneering scie. |
2025-01-13 11:00:00 | Daiichi Sankyo Acquires Intellectual Property Rights For Anti-ta-muc1 Antibody In Ds-3939 From Glycotope Gmbh Tokyo & basking ridge, n.j.--(business wire)--daiichi sankyo company, ltd (tse: 4568) announced today that it will pay glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (ta-muc1) antibody, gatipotuzumab. such payment by daiichi sankyo satisfies all potential clinical, regulatory and sales milestone payments, as well as royalties of products that include gatipotuzumab as part of a 2018 licensing agreement between the parties. in 2018, daiichi s. |
2024-08-31 11:00:00 | Daiichi Sankyo Shines A Light On Inequalities And Unmet Needs In Care As Part Of Its Commitment To People With Cardiovascular Disease Munich--(business wire)--daiichi sankyo europe, (hereafter, daiichi sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (cv) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. the announcement follows the presentation of data from sub-analyses of the santorini observational study and etna-af (edoxaban treatment in routine clinical practice in patients with nonvalvular atrial fibrill. |
2024-07-10 06:06:00 | Daiichi Sankyo Opens New Affiliate For Oncology In Greece Athens, greece--(business wire)--daiichi sankyo (tse: 4568) today announced that it has opened a new affiliate for its oncology business in athens, greece. the establishment highlights the companyโs strong commitment to addressing treatment needs of people living with cancer in the european region. thomais konstantopoulou has been appointed country manager, daiichi sankyo greece single member s.a. โwe are very happy to open yet another new affiliate in europe to bring our innovative medicines t. |
2024-05-27 21:00:00 |
|
2024-01-03 07:00:00 |
|
2023-12-12 03:18:00 |
|
2023-12-01 08:00:00 |
|
2023-11-06 02:00:00 |
|
2023-08-26 11:00:00 |
|
2023-08-16 10:00:00 |
|
2022-07-19 19:52:00 |
|
2022-06-27 02:00:00 |
|
2021-12-16 18:00:00 |
|

๐ฐ Browse additional press releases for Daiichi Sankyo!
Sign up for free or log in๐ Free download! "The Checklist Value Investor โ A Smarter Way to Pick Stocks"